Significant Growth Improvements for Tube-Fed Children
Alcresta Therapeutics, Inc., has released promising clinical data highlighting advancements in the growth of children aged 1 to 5 years using RELiZORB. This enzyme-based product aims to support the nutritional needs of tube-fed patients who often face challenges with fat absorption.
Clinical Findings on RELiZORB Usage
The recently published results in the journal Nutrients reveal substantial enhancements in weight and body mass index (BMI) z-scores following RELiZORB use. As many children requiring tube feedings struggle with fat malabsorption, this solution addresses such nutritional deficits, fostering better growth and development during critical stages of childhood.
Research Methodology
This retrospective analysis evaluated children who began using RELiZORB between the ages of 1 and less than 5. The study tracked changes in body weight z-scores over a span of 12 months, with secondary assessments on BMI percentiles and weight z-scores noted at 3, 6, and 9 months. The data indicated statistically significant improvements, with tangible benefits observed as early as three months.
Safety and Efficacy of RELiZORB
Importantly, no new safety concerns arose from the application of RELiZORB throughout the study. Most participants had cystic fibrosis, while others experienced varying malabsorptive conditions. RELiZORB stands out as the sole FDA-cleared enzyme device designed to replicate pancreatic lipase function, enhancing fat absorption in tube-fed individuals.
Regulatory Milestones and Innovations
Alcresta's RELiZORB received FDA clearance for all ages, including neonates and infants. This move follows encouraging real-world data showcasing improvements in weight z-scores in younger patients, underscoring RELiZORB's broad applicability across various needs.
Expert Insight on Clinical Outcomes
Dan Orlando, CEO at Alcresta, emphasized that this research extends the existing clinical evidence supporting RELiZORB's ability to positively influence nutritional care and growth outcomes in pediatric patients requiring enteral feeding.
About RELiZORB and Alcresta Therapeutics
RELiZORB is specifically formulated to assist pediatric and adult patients during enteral feeding, providing essential hydrolysis of fats. It is crafted using advanced enzyme immobilization technology known as iLipase, allowing for efficient fat breakdown prior to ingestion.
Alcresta Therapeutics focuses on developing pioneering enzyme-based products designed to mitigate challenges associated with gastrointestinal disorders. They currently market RELiZORB, which is crucial for individuals experiencing pancreatic insufficiency due to conditions like cystic fibrosis and pancreatitis.
As Alcresta continues to innovate, they have plans for a platform application targeting prematurely born infants in the NICU, ensuring improved care for the most vulnerable patients.
Frequently Asked Questions
What is RELiZORB?
RELiZORB is an enzyme cartridge designed to assist in the digestion of fats for tube-fed patients, specifically those with pancreatic insufficiency.
How does RELiZORB improve nutritional outcomes?
By mimicking pancreatic lipase, RELiZORB breaks down dietary fats into absorbable forms, enhancing nutritional intake for pediatric patients.
What were the study's main findings?
The study showed significant improvements in weight and BMI z-scores in children aged 1 to 5 who used RELiZORB, with benefits noted as early as three months into treatment.
Is RELiZORB safe for all age groups?
Yes, RELiZORB is FDA-cleared for use in patients of all ages, including neonates and infants.
What is Alcresta Therapeutics' mission?
Alcresta aims to develop innovative products that address complex nutritional needs in patients with gastrointestinal disorders and rare diseases, improving their quality of life.
